ProShare Advisors
CATX icon

ProShare Advisors’s Perspective Therapeutics CATX Stock Holding History

ProShare Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.1K Buy
+13,522
New +$51.1K ﹤0.01% 1850
2026
Q1 		– Sell
-10,889
Closed -$29.9K – 1893
2025
Q4 		$29.9K Buy
10,889
+699
+7% +$1.99K ﹤0.01% 1999
2025
Q3 		$35K Sell
10,190
-2,030
-17% -$7.4K ﹤0.01% 1961
2025
Q2 		$42K Buy
12,220
+518
+4% +$1.37K ﹤0.01% 2014
2025
Q1 		$24.9K Sell
11,702
-3,523
-23% -$10.6K ﹤0.01% 2022
2024
Q4 		$48.6K Buy
15,225
+5,011
+49% +$40.9K ﹤0.01% 2180
2024
Q3 		$136K Buy
+10,214
New +$136K ﹤0.01% 1829

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

ProShare Advisors's CATX Position: Q2 2026 in Review

ProShare Advisors opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 13,522 shares worth $46.1K. The stake represents ﹤0.01% of the portfolio and ranks #1850 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in CATX as recently as Q4 2025.

ProShare Advisors first reported a position in CATX in Q3 2024 and has held it in 7 quarters since. The position peaked at $136K in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • ProShare Advisors held 13,522 shares of Perspective Therapeutics worth $46.1K as of Q2 2026.
  • Perspective Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1850 holding.
  • ProShare Advisors first reported a position in Perspective Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • ProShare Advisors's Perspective Therapeutics position peaked at $136K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.